Translational Genomics & Molecular Biomarkers
Authoritative genomic profiling covering targeted NGS oncogene panels, clinical exome sequencing, liquid biopsy ctDNA, metagenomics, and epigenetic methylation clocks with strict scientific classification.
30-Gene Hereditary Cancer Germline NGS Panel with High-Resolution CNV
Identifies pathogenic germline variants conferring lifetime cancer predisposition for Hereditary Breast and Ovarian Cancer (HBOC), Lynch Syndrome, and Li-Fraumeni Syndrome.
Clinical Exome Sequencing (Mendelian Phenome > 6,000 Disease Genes)
Definitive molecular diagnosis for complex neurodevelopmental delays, inborn errors of metabolism, rare syndromic presentations, and atypical pediatric disorders.
Somatic Solid Tumor 52-Gene Comprehensive Theranostic NGS Panel
Identifies actionable predictive biomarkers for FDA/EMA approved targeted therapies (Osimertinib, Sotorasib, Dabrafenib+Trametinib, Larotrectinib, Trastuzumab) and resistance mutations.
Cell-Free circulating Tumor DNA (ctDNA) Liquid Biopsy Multiplex Assay
Minimally invasive molecular profiling for monitoring minimal residual disease (MRD), evaluating therapeutic response, and detecting emergent secondary resistance mechanisms (e.g. EGFR T790M/C797S or ESR1 mutations) prior to radiographic progression.
Clinical Metagenomic Next-Generation Sequencing (mNGS) for Pathogen ID
Unbiased, hypothesis-free detection of occult, fastidious, or unculturable pathogens directly from sterile clinical fluids in critically ill patients.
Genome-Wide DNA Methylation Biological Aging Clock Analysis (Horvath / GrimAge)
Quantifies epigenetic biological age acceleration relative to chronological age for longevity research and translational wellness studies. Strictly classified for Research & Investigational Use.
Circulating MicroRNA (miRNA) Hepatic & Fibrotic Biomarker Panel
Investigational non-coding microRNA expression signatures evaluated in metabolic dysfunction-associated steatohepatitis (MASH) and systemic fibrogenesis research.